Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): A single-arm, prospective, phase 2 clinical trial.

Shouyong Liu, Le Qu, Song Xue et al.|Journal of Clinical Oncology|2025

Cited by 2